The 4th JAK inhibitor, Cibinqo, is nearing insurance reimbursement in Korea.

According to industry sources, Pfizer Korea’s new Janus kinases (JAK) inhibitor ‘Cibinqo (abrocitinib)’ passed the review of the National Health Insurance Review and Assessment Service’s Drug Reimbursement Standard Subcommittee.

The company applied for Cibinqo’s reimbursement in April. Its competitors -’ Lilly Korea’s ‘Olumiant (baricitinib)' and Abbvie’s ‘Rinvoq (upadacitinib)’ – have already been receiving reimbursement for the atopic dermatitis indication since May. Considering how the company made the strategic move to accept the weighted average price of its alternative drugs, its progress